Biotechnology

Sep 23, 2026

Enveda Biosciences raises $311M to advance AI-designed drugs for immune diseases and obesity

Enveda Biosciences secures $311M in Series E funding to progress its AI-designed drug pipeline, including treatments for eczema and obesity.